Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review

Jones, Heidi; Green, Victoria; England, James; Greenman, John

Abstract

Thyroid cancer incidence and related mortality is increasing year-on-year, and although treatment for early disease with surgery and radioiodine results in a 98% 5-year survival rate, recurrence and treatment refractory disease is evident in an unacceptable number of patients. Alternative treatment regimens have therefore been sought in the form of tyrosine kinase inhibitors, immunotherapy, vaccines, chimeric antigen receptor T-cell therapy and oncolytic viruses. The current review aims to consolidate knowledge and highlight the latest clinical trials using secondary therapies in thyroid cancer treatment, focusing on both in vitro and in vivo studies, which have investigated therapies other than radioiodine. Lay abstract The rates of thyroid cancer and related deaths are increasing. Differentiated thyroid cancer is the most common type of thyroid cancer. Early disease can be treated with surgery and radioactive iodine with very good outcomes. However, this therapy does not work for a small number of patients making it important to find different (secondary) treatment options. This review summarizes the results of published research about secondary treatment options for differentiated thyroid cancer. Ongoing research including laboratory-based and clinical trials are also highlighted.

Citation

Jones, H., Green, V., England, J., & Greenman, J. (2021). Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review. Future Science OA, 7(7), https://doi.org/10.2144/fsoa-2021-0041

• Journal Article Type: Review
• Acceptance Date: May 27, 2021
• Online Publication Date: Jun 15, 2021
• Publication Date: 2021-08
• Deposit Date: Jan 5, 2022
• Publicly Available Date: Jan 5, 2022
• Journal: Future Science OA
• Print ISSN: 2056-5623
• Electronic ISSN: 2056-5623
• Publisher: Future Science
• Peer Reviewed: Peer Reviewed
• Volume: 7
• Issue: 7
• DOI: https://doi.org/10.2144/fsoa-2021-0041
• Keywords: Chimeric antigen receptor T-cell therapy; Immunotherapy; Oncolytic viruses; Secondary therapy; Thyroid cancer; Tyrosine kinase inhibitors
• Public URL: https://hull-repository.worktribe.com/output/3821213